Prevention of Pneumonia and Invasive Disease Caused by the Serotypes in 13vPnC

Clinical trial pipeline · Data from ClinicalTrials.gov

Total trials

Actively recruiting

Phase 3 trials

Completed

This study is to describe the safety and immunogenicity of 13vPnC in Indian adults 50 to 65 years of age and in Indian children 6 to 17 years of age.